Humira decline to be offset by AbbVie’s strong immunology portfolio, says analyst

For 20 years, US pharma major AbbVie’s (NYSE: ABBV) Humira (adalimumab) has been one of the world’s top-selling products.

However, the US drug expiry in January 2023 resulted in a 32% decline in sales of Humira in 2023, accompanied by a 7% drop in the company’s total revenue for that year.

As further sharp declines are expected for Humira, AbbVie has strategically pivoted to alternative immunology products to bolster its revenue streams. As such, two drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), are emerging as key replacements. These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says pharma analytics company GlobalData